LymphomaPhase 3NCT00006721
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma
A Phase 3 study testing rituximab, cyclophosphamide and doxorubicin in people with Lymphoma, run by SWOG Cancer Research Network at 259 sites in United States.
Trial summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver radioactive tumor-killing substances to them without harming normal cells. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Lymphoma
- What is being tested?
- rituximab, cyclophosphamide and doxorubicin
- Type of treatment
- Pill or oral medicine, Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 571 participants
- Where
- 259 sitesUnited States
- Study dates
- Mar 2001to Dec 2025
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
DISEASE CHARACTERISTICS:
- Histologically confirmed previously untreated bulky stage II or stage III or IV follicular non-Hodgkin's lymphoma
- Grade I-III disease
- Cluster of differentiation antigen 20 (CD20) antigen positive
- Fewer than 5,000/mm^3 circulating lymphoid cells on a white blood cell (WBC) differential count
- Bidimensionally measurable disease
- Bone marrow aspiration and biopsy within the past 42 days
- No clinical evidence of central nervous system (CNS) involvement by lymphoma
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- Zubrod 0-2
Life expectancy:
- Not specified
Hematopoietic:
- See Disease Characteristics
- Granulocyte count greater than 1,500/mm^3
- Platelet count greater than 100,000/mm^3
Hepatic:
- Not specified
Renal:
- Not specified
Cardiovascular:
- No impaired cardiac status, including:
- Severe coronary artery disease
- Cardiomyopathy
- Congestive heart failure
- Serious arrhythmia
- Ejection fraction at least lower limit of normal by Multi Gated Acquisition Scan (MUGA) or 2-D echocardiogram for questionable cardiac history
Other:
- No hypersensitivity to iodine
- Not pregnant or nursing
- Fertile patients must use effective contraception during and for 6 months after study participation
- HIV negative
- No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- No prior monoclonal antibodies for cancer
Chemotherapy:
- No prior chemotherapy for lymphoma
- Prior prednisone for non-lymphoma related illnesses allowed
Endocrine therapy:
- Not specified
Radiotherapy:
- No prior radiotherapy for lymphoma
Surgery:
- See Disease Characteristics
Trial locations and contacts
259 sites in 1 country.
259 sites in 1 country
United States259 sites
McDowell Cancer Center at Akron General Medical Center
Akron, Ohio, 44307
Saint Anthony's Hospital at Saint Anthony's Health Center
Alton, Illinois, 62002
Alaska Regional Hospital Cancer Center
Anchorage, Alaska, 99508
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109-0942
Piedmont Hospital
Atlanta, Georgia, 30309
Northside Hospital Cancer Center
Atlanta, Georgia, 30342-1611
Saint Joseph's Hospital of Atlanta
Atlanta, Georgia, 30342-1701
CCOP - Atlanta Regional
Atlanta, Georgia, 30342
Rush-Copley Cancer Care Center
Aurora, Illinois, 60504
WellStar Cobb Hospital
Austell, Georgia, 30106
Greenebaum Cancer Center at University of Maryland Medical Center
Baltimore, Maryland, 21201
Alvin and Lois Lapidus Cancer Institute at Sinai Hospital
Baltimore, Maryland, 21215
Battle Creek Health System Cancer Care Center
Battle Creek, Michigan, 49017
Bay Regional Medical Center
Bay City, Michigan, 48708
St. Francis Hospital and Health Centers - Beech Grove Campus
Beech Grove, Indiana, 46107
Mary Rutan Hospital
Bellefontaine, Ohio, 43311
St. Joseph Cancer Center
Bellingham, Washington, 98225
Alta Bates Summit Comprehensive Cancer Center
Berkeley, California, 94704
Mecosta County Medical Center
Big Rapids, Michigan, 49307
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
Hematology-Oncology Centers of the Northern Rockies - Billings
Billings, Montana, 59101
Northern Rockies Radiation Oncology Center
Billings, Montana, 59101
St. Vincent Healthcare Cancer Care Services
Billings, Montana, 59101
Billings Clinic - Downtown
Billings, Montana, 59107-7000
St. Joseph Medical Center
Bloomington, Illinois, 61701
Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center
Boise, Idaho, 83706
Mountain States Tumor Institute at St. Luke's Regional Medical Center
Boise, Idaho, 83712
Bozeman Deaconess Cancer Center
Bozeman, Montana, 59715
Olympic Hematology and Oncology
Bremerton, Washington, 98310
Roswell Park Cancer Institute
Buffalo, New York, 14263-0001
Peninsula Medical Center
Burlingame, California, 94010
Lahey Clinic Medical Center - Burlington
Burlington, Massachusetts, 01805
St. James Healthcare Cancer Care
Butte, Montana, 59701
Graham Hospital
Canton, Illinois, 61520
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
Memorial Hospital
Carthage, Illinois, 62321
Cancer Center of Kansas, PA - Chanute
Chanute, Kansas, 66720
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, 27599-7295
Roper St. Francis Cancer Center at Roper Hospital
Charleston, South Carolina, 29401
Hollings Cancer Center at Medical University of South Carolina
Charleston, South Carolina, 29425
Saint Luke's Hospital
Chesterfield, Missouri, 63017
University of Illinois Cancer Center
Chicago, Illinois, 60612-7243
University of Chicago Cancer Research Center
Chicago, Illinois, 60637-1470
Adena Regional Medical Center
Chillicothe, Ohio, 45601
Good Samaritan Hospital Cancer Treatment Center
Cincinnati, Ohio, 45220
Charles M. Barrett Cancer Center at University Hospital
Cincinnati, Ohio, 45267
Cleveland Clinic Cancer Center at Fairview Hospital
Cleveland, Ohio, 44111
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195
Veterans Affairs Medical Center - Columbia (Truman Memorial)
Columbia, Missouri, 65201
Ellis Fischel Cancer Center at University of Missouri - Columbia
Columbia, Missouri, 65203
Palmetto Health South Carolina Cancer Center
Columbia, South Carolina, 29203
Riverside Methodist Hospital Cancer Care
Columbus, Ohio, 43214-3998
CCOP - Columbus
Columbus, Ohio, 43215
Grant Medical Center Cancer Care
Columbus, Ohio, 43215
Mount Carmel Health - West Hospital
Columbus, Ohio, 43222
Doctors Hospital at Ohio Health
Columbus, Ohio, 43228
Grandview Hospital
Dayton, Ohio, 45405
Good Samaritan Hospital
Dayton, Ohio, 45406
David L. Rike Cancer Center at Miami Valley Hospital
Dayton, Ohio, 45409
Samaritan North Cancer Care Center
Dayton, Ohio, 45415
Veterans Affairs Medical Center - Dayton
Dayton, Ohio, 45428
CCOP - Dayton
Dayton, Ohio, 45429
Charles B. Eberhart Cancer Center at DeKalb Medical Center
Decatur, Georgia, 30033
Decatur Memorial Hospital Cancer Care Institute
Decatur, Illinois, 62526
Grady Memorial Hospital
Delaware, Ohio, 43015
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201-1379
Josephine Ford Cancer Center at Henry Ford Hospital
Detroit, Michigan, 48202
Cancer Center of Kansas, PA - Dodge City
Dodge City, Kansas, 67801
Duke Comprehensive Cancer Center
Durham, North Carolina, 27710
Cancer Center of Kansas, PA - El Dorado
El Dorado, Kansas, 67042
Elkhart General Hospital
Elkhart, Indiana, 46515
Eureka Community Hospital
Eureka, Illinois, 61530
Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital
Fairbanks, Alaska, 99701
St. Francis Hospital
Federal Way, Washington, 98003
Blanchard Valley Medical Associates
Findlay, Ohio, 45840
Dwight David Eisenhower Army Medical Center
Fort Gordon, Georgia, 30905-5650
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center
Fort Smith, Arkansas, 72903
Middletown Regional Hospital
Franklin, Ohio, 45005-1066
Northeast Georgia Medical Center
Gainesville, Georgia, 30501
Galesburg Clinic, PC
Galesburg, Illinois, 61401
Galesburg Cottage Hospital
Galesburg, Illinois, 61401
Southeast Missouri Regional Cancer Center at Southeast Missouri Hospital
Gape Girardeau, Missouri, 63701
Wayne Memorial Hospital, Incorporated
Goldsboro, North Carolina, 27534
Butterworth Hospital at Spectrum Health
Grand Rapids, Michigan, 49503
CCOP - Grand Rapids
Grand Rapids, Michigan, 49503
Lacks Cancer Center at Saint Mary's Health Care
Grand Rapids, Michigan, 49503
Big Sky Oncology
Great Falls, Montana, 59405-5309
Great Falls Clinic - Main Facility
Great Falls, Montana, 59405
Sletten Cancer Institute at Benefis Healthcare
Great Falls, Montana, 59405
Study site
Great Falls, Montana, 59405
Marin Cancer Institute at Marin General Hospital
Greenbrae, California, 94904
Sutter Health - Western Division Cancer Research Group
Greenbrae, California, 94904
CCOP - Greenville
Greenville, South Carolina, 29615
Legacy Mount Hood Medical Center
Gresham, Oregon, 97030
Helen and Harry Gray Cancer Center at Hartford Hospital
Hartford, Connecticut, 06102-5037
Mason District Hospital
Havana, Illinois, 62644
St. Peter's Hospital
Helena, Montana, 59601
Veterans Affairs Medical Center - Hines
Hines, Illinois, 60141
Holland Community Hospital
Holland, Michigan, 49423
Tripler Army Medical Center
Honolulu, Hawaii, 96859
Hopedale Medical Complex
Hopedale, Illinois, 61747
Cancer Center of Kansas-Independence
Independence, Kansas, 67301
Independence Regional Health Center
Independence, Missouri, 64050
Community Oncology Group at Cleveland Clinic Cancer Center
Independence, Ohio, 44131
University of Mississippi Cancer Clinic
Jackson, Mississippi, 39216
Joliet Oncology-Hematology Associates, Limited - West
Joliet, Illinois, 60435
Freeman Cancer Institute at Freeman Health System
Joplin, Missouri, 64804
St. John's Regional Medical Center
Joplin, Missouri, 64804
Borgess Medical Center
Kalamazoo, Michigan, 49001
West Michigan Cancer Center
Kalamazoo, Michigan, 49007-3731
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
Glacier Oncology, PLLC
Kalispell, Montana, 59901
Kalispell Medical Oncology at KRMC
Kalispell, Montana, 59901
Kalispell Regional Medical Center
Kalispell, Montana, 59901
Providence Medical Center
Kansas City, Kansas, 66112
Truman Medical Center - Hospital Hill
Kansas City, Missouri, 64108
Saint Luke's Cancer Institute at Saint Luke's Hospital
Kansas City, Missouri, 64111
Kansas City Cancer Center at St. Joseph's Medical Mall
Kansas City, Missouri, 64114
St. Joseph Medical Center
Kansas City, Missouri, 64114
North Kansas City Hospital
Kansas City, Missouri, 64116
Parvin Radiation Oncology
Kansas City, Missouri, 64116
CCOP - Kansas City
Kansas City, Missouri, 64131
Radiation Oncology Associates of Kansas City at Northland Radiation Oncology Center
Kansas City, Missouri, 64154
Good Samaritan Cancer Center at Good Samaritan Hospital
Kearney, Nebraska, 68848-1990
Columbia Basin Hematology
Kennewick, Washington, 99336
Charles F. Kettering Memorial Hospital
Kettering, Ohio, 45429
Cancer Center of Kansas, PA - Kingman
Kingman, Kansas, 67068
Cascade Cancer Center at Evergreen Hospital Medical Center
Kirkland, Washington, 98033
Howard Community Hospital
Kokomo, Indiana, 46904
Center for Cancer Therapy at LaPorte Hospital and Health Services
La Porte, Indiana, 46350
Center for Cancer Care and Research at Watson Clinic, LLP
Lakeland, Florida, 33805
Fairfield Medical Center
Lancaster, Ohio, 43130
Lawrence Memorial Hospital
Lawrence, Kansas, 66044
Gwinnett Medical Center
Lawrenceville, Georgia, 30045
Southwest Medical Center
Liberal, Kansas, 67901
St. Rita's Medical Center
Lima, Ohio, 45801
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
Joe Arrington Cancer Research and Treatment Center
Lubbock, Texas, 79410-1894
UMC Southwest Cancer and Research Center
Lubbock, Texas, 79415-3364
Lynchburg Hematology-Oncology Clinic
Lynchburg, Virginia, 24501
McDonough District Hospital
Macomb, Illinois, 61455
Kennestone Cancer Center at Wellstar Kennestone Hospital
Marietta, Georgia, 30060
Strecker Cancer Center at Marietta Memorial Hospital
Marietta, Ohio, 45750
Cardinal Bernardin Cancer Center at Loyola University Medical Center
Maywood, Illinois, 60153
Saint Anthony Memorial Health Centers
Michigan City, Indiana, 46360
Tucker Center for Cancer Care at Orange Regional Medical Center
Middletown, New York, 10940-4199
Providence Milwaukie Hospital
Milwaukie, Oregon, 97222
Community Medical Center
Missoula, Montana, 59801
Guardian Oncology and Center for Wellness
Missoula, Montana, 59804
Montana Cancer Specialists at Montana Cancer Center
Missoula, Montana, 59807-7877
Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
Missoula, Montana, 59807
Good Samaritan Regional Health Center
Mount Vernon, Illinois, 62864
Hackley Hospital
Muskegon, Michigan, 49442
Edward Hospital Cancer Center
Naperville, Illinois, 60540
New York Weill Cornell Cancer Center at Cornell University
New York, New York, 10021
Licking Memorial Cancer Care Program at Licking Memorial Hospital
Newark, Ohio, 43055
Cancer Center of Kansas, PA - Newton
Newton, Kansas, 67114
BroMenn Regional Medical Center
Normal, Illinois, 61761
Community Cancer Center
Normal, Illinois, 61761
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
Omaha, Nebraska, 68198-6805
Community Hospital of Ottawa
Ottawa, Illinois, 61350
Oncology Hematology Associates of Central Illinois, PC - Ottawa
Ottawa, Illinois, 61350
Menorah Medical Center
Overland Park, Kansas, 66209
Johnson County Radiation Therapy
Overland Park, Kansas, 66210
Desert Regional Medical Center Comprehensive Cancer Center
Palm Springs, California, 92262
Cancer Center of Kansas, PA - Parsons
Parsons, Kansas, 67357
Cancer Treatment Center at Pekin Hospital
Pekin, Illinois, 61554
Sacred Heart Cancer Center at Sacred Heart Hospital
Pensacola, Florida, 32504
West Florida Cancer Institute at West Florida Hospital - Pensacola
Pensacola, Florida, 32514
Proctor Hospital
Peoria, Illinois, 61614
CCOP - Illinois Oncology Research Association
Peoria, Illinois, 61615
Oncology Hematology Associates of Central Illinois, PC - Peoria
Peoria, Illinois, 61615
Methodist Medical Center of Illinois
Peoria, Illinois, 61636
OSF St. Francis Medical Center
Peoria, Illinois, 61637
Illinois Valley Community Hospital
Peru, Illinois, 61354
Berkshire Hematology Oncology, PC
Pittsfield, Massachusetts, 01201
Olympic Medical Center
Port Angeles, Washington, 98362
Legacy Good Samaritan Hospital & Comprehensive Cancer Center
Portland, Oregon, 97210
Providence Cancer Center at Providence Portland Medical Center
Portland, Oregon, 97213-2967
Adventist Medical Center
Portland, Oregon, 97216
CCOP - Columbia River Oncology Program
Portland, Oregon, 97225
Providence St. Vincent Medical Center
Portland, Oregon, 97225
Legacy Emanuel Hospital and Health Center and Children's Hospital
Portland, Oregon, 97227
Cancer Center of Kansas, PA - Pratt
Pratt, Kansas, 67124
Perry Memorial Hospital
Princeton, Illinois, 61356
Good Samaritan Cancer Center
Puyallup, Washington, 98372
Valley Medical Center
Renton, Washington, 98055
Reid Hospital & Health Care Services
Richmond, Indiana, 47374
Southern Regional Medical Center
Riverdale, Georgia, 30274-2600
James P. Wilmot Cancer Center at University of Rochester Medical Center
Rochester, New York, 14642
University of California Davis Cancer Center
Sacramento, California, 95817
Lakeland Regional Cancer Care Center - St. Joseph
Saint Joseph, Michigan, 49085
Oncology Care Associates, PLLC
Saint Joseph, Michigan, 49085
Heartland Regional Medical Center
Saint Joseph, Missouri, 64506
Cancer Center of Kansas, PA - Salina
Salina, Kansas, 67042
Tammy Walker Cancer Center at Salina Regional Health Center
Salina, Kansas, 67401
Huntsman Cancer Institute at University of Utah
Salt Lake City, Utah, 84112
California Pacific Medical Center - California Campus
San Francisco, California, 94118
CCOP - Virginia Mason Research Center
Seattle, Washington, 98101
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98104
Harborview Medical Center
Seattle, Washington, 98104
Minor and James Medical, PLLC
Seattle, Washington, 98104
Group Health Central Hospital
Seattle, Washington, 98112
Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
Seattle, Washington, 98122-4307
Polyclinic First Hill
Seattle, Washington, 98122
University Cancer Center at University of Washington Medical Center
Seattle, Washington, 98195-6043
Shawnee Mission Medical Center
Shawnee Mission, Kansas, 66204
Welch Cancer Center at Sheridan Memorial Hospital
Sheridan, Wyoming, 82801
Siouxland Hematology-Oncology Associates, LLP
Sioux City, Iowa, 51101
Mercy Medical Center - Sioux City
Sioux City, Iowa, 51104
St. Luke's Regional Medical Center
Sioux City, Iowa, 51104
CCOP - Northern Indiana CR Consortium
South Bend, Indiana, 46601
Memorial Hospital of South Bend
South Bend, Indiana, 46601
Saint Joseph Regional Medical Center
South Bend, Indiana, 46617
Cancer Care Northwest - Spokane South
Spokane, Washington, 99202
St. Margaret's Hospital
Spring Valley, Illinois, 61362
Regional Cancer Center at Memorial Medical Center
Springfield, Illinois, 62781-0001
CCOP - Cancer Research for the Ozarks
Springfield, Missouri, 65802
St. John's Regional Health Center
Springfield, Missouri, 65804
Hulston Cancer Center at Cox Medical Center South
Springfield, Missouri, 65807
Mercy Medical Center
Springfield, Ohio, 45504
Community Hospital of Springfield and Clark County
Springfield, Ohio, 45505
Midwest Hematology Oncology Group, Incorporated
St Louis, Missouri, 63109
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
St Louis, Missouri, 63110
CCOP - St. Louis-Cape Girardeau
St Louis, Missouri, 63141
David C. Pratt Cancer Center at St. John's Mercy
St Louis, Missouri, 63141
Stanford Cancer Center
Stanford, California, 94305-5824
Franciscan Cancer Center at St. Joseph Medical Center
Tacoma, Washington, 98405-3004
Allenmore Hospital
Tacoma, Washington, 98405
CCOP - Northwest
Tacoma, Washington, 98405
MultiCare Regional Cancer Center at Tacoma General Hospital
Tacoma, Washington, 98405
St. Clare Hospital
Tacoma, Washington, 98499
Cotton-O'Neil Cancer Center
Topeka, Kansas, 66606
Munson Medical Center
Traverse City, Michigan, 49684
UVMC Cancer Care Center at Upper Valley Medical Center
Troy, Ohio, 45373-1300
Legacy Meridian Park Hospital
Tualatin, Oregon, 97062
Carle Cancer Center at Carle Foundation Hospital
Urbana, Illinois, 61801
CCOP - Carle Cancer Center
Urbana, Illinois, 61801
Pearlman Comprehensive Cancer Center at South Georgia Medical Center
Valdosta, Georgia, 31603
Sutter Solano Medical Center
Vallejo, California, 94589
Southwest Washington Medical Center Cancer Center
Vancouver, Washington, 98668
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
Washington D.C., District of Columbia, 20007
Cancer Center of Kansas, PA - Wellington
Wellington, Kansas, 67152
Wenatchee Valley Medical Center
Wenatchee, Washington, 98801-2028
Mount Carmel St. Ann's Cancer Center
Westerville, Ohio, 43081
Schiffler Cancer Center at Wheeling Hospital
Wheeling, West Virginia, 26003
Associates in Womens Health, PA - North Review
Wichita, Kansas, 67208
Cancer Center of Kansas, PA - Medical Arts Tower
Wichita, Kansas, 67208
Cancer Center of Kansas, PA - Wichita
Wichita, Kansas, 67214
CCOP - Wichita
Wichita, Kansas, 67214
Via Christi Cancer Center at Via Christi Regional Medical Center
Wichita, Kansas, 67214
Wesley Medical Center
Wichita, Kansas, 67214
Clinton Memorial Hospital
Wilmington, Ohio, 45177
Cancer Center of Kansas, PA - Winfield
Winfield, Kansas, 67156
Cleveland Clinic - Wooster
Wooster, Ohio, 44691
Metro Health Hospital
Wyoming, Michigan, 49519
Ruth G. McMillan Cancer Center at Greene Memorial Hospital
Xenia, Ohio, 45385
North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
Yakima, Washington, 98902
Genesis - Good Samaritan Hospital
Zanesville, Ohio, 43701
About this study
Official title: A Phase III Trial of CHOP Plus Rituximab vs CHOP Plus Iodine-131-Labeled Monoclonal Anti-B1 Antibody (Tositumomab) for Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver radioactive tumor-killing substances to them without harming normal cells. It is not yet known which monoclonal antibody plus combination chemotherapy regimen is more effective in treating non-Hodgkin's lymphoma.
PURPOSE: This randomized phase III trial is comparing 2 different monoclonal antibodies given together with combination chemotherapy to see how well they work in treating patients with newly-diagnosed non-Hodgkin's lymphoma.
Read the detailed description
OBJECTIVES:
- Compare the progression-free survival and overall survival of patients with newly diagnosed follicular non-Hodgkin's lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with or without either rituximab or iodine I 131 tositumomab (monoclonal antibody anti-B1). (CHOP chemotherapy alone arm closed to accrual as of 12/15/02)
- Compare the response rate of these patients treated with these regimens.
- Compare the toxic effects of these regimens in these patients.
- Compare the molecular remission rates of this patient population treated with these regimens.
- Determine the incidence and time to development of human anti-mouse antibody positivity.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to whether microglobulin is greater than upper limit of normal (yes vs no). Patients are randomized to 1 of 3 treatment arms. (Arm I closed to accrual as of 12/15/02)
- Arm I (CHOP only): Patients receive cyclophosphamide IV over 15 minutes, doxorubicin IV over 5-20 minutes, and vincristine IV over 5-15 minutes on day 1. Patients also receive oral prednisone daily on days 1-5. Treatment continues every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. (Arm I closed to accrual as of 12/15/02)
- Arm II (CHOP + rituximab): Patients receive cyclophosphamide IV over 15 minutes, doxorubicin IV over 5-20 minutes, and vincristine IV over 5-15 minutes on days 8, 29, 50, 71, 92, and 113. Patients also receive oral prednisone daily on days 8-12, 29-33, 50-54, 71-75, and 113-117 and rituximab IV over 4-6 hours on days 1, 6, 48, 90, 134, and 141.
- Arm III (CHOP + tositumomab): Patients receive chemotherapy as in arm I and tositumomab (monoclonal antibody anti-B1) IV over 1 hour followed by iodine I 131 tositumomab IV over 20 minutes on days 134 and 141.
Patients are followed on day 200, at 1 year, every 6 months for 2 years, and then annually thereafter.
PROJECTED ACCRUAL: Approximately 500 patients (250 per treatment arm) will be accrued for this study within 5.5 years. (Arm I closed to accrual as of 12/15/02)
- Conditions
- Lymphoma
- Being tested
- rituximab, cyclophosphamide, doxorubicin, prednisone, vincristine
- Keywords
- stage III grade 1 follicular lymphoma, stage III grade 2 follicular lymphoma, stage III grade 3 follicular lymphoma, stage IV grade 1 follicular lymphoma, stage IV grade 2 follicular lymphoma, stage IV grade 3 follicular lymphoma, contiguous stage II grade 1 follicular lymphoma, contiguous stage II grade 2 follicular lymphoma, contiguous stage II grade 3 follicular lymphoma, noncontiguous stage II grade 1 follicular lymphoma, noncontiguous stage II grade 2 follicular lymphoma, noncontiguous stage II grade 3 follicular lymphoma
- Medical subject headings
- Lymphoma, Lymphoma, Follicular
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
rituximabBiological
Also called rituxan
Given IV
cyclophosphamideDrug
Also called cytoxan
Given IV
doxorubicinDrug
Also called adriamycin
Given IV
prednisoneDrug
Also called steroid
Given orally
vincristineDrug
Also called oncovin
Given IV
tositumomabRadiation
Given IV
| Study group | Role | What they receive |
|---|---|---|
| Arm I (CHOP only) | Active comparator | Patients receive cyclophosphamide IV over 15 minutes, doxorubicin IV over 5-20 minutes, and vincristine IV over 5-15 minutes on day
1. Patients also receive oral prednisone daily on days 1-5. Treatment continues every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. (Arm I closed to accrual as of 12/15/02) Receives: Drug: cyclophosphamide; Drug: doxorubicin; Drug: prednisone; Drug: vincristine |
| Arm II (CHOP + rituximab) | Experimental | Patients receive cyclophosphamide IV over 15 minutes, doxorubicin IV over 5-20 minutes, and vincristine IV over 5-15 minutes on days 8, 29, 50, 71, 92, and 113. Patients also receive oral prednisone daily on days 8-12, 29-33, 50-54, 71-75, and 113-117 and rituximab IV over 4-6 hours on days 1, 6, 48, 90, 134, and 141. Receives: Biological: rituximab; Drug: cyclophosphamide; Drug: doxorubicin; Drug: prednisone; Drug: vincristine |
| Arm III (CHOP + tositumomab) | Experimental | Patients receive chemotherapy as in arm I and tositumomab (monoclonal antibody anti-B1) IV over 1 hour followed by iodine I 131 tositumomab IV over 20 minutes on days 134 and 141. Receives: Drug: cyclophosphamide; Drug: doxorubicin; Drug: prednisone; Drug: vincristine; Radiation: tositumomab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Progression-free Survival at 2 Years
Measured from time of registration to date of of first observation of progression/relapse, or death due to any cause, or last contact date
Measured: 0-2 years
Progression-free Survival at 5 Years
Measured from time of registration to date of of first observation of progression/relapse, or death due to any cause, or last contact date
Measured: 0-5 years
Overall Survival at 2 Years
Measured from date of registration to date of death due to any cause
Measured: 0-2 years
Overall Survival at 5 Years
Measured from date of registration to date of death due to any cause
Measured: 0-5 years
Secondary outcomes (2)
Objective Response (Confirmed and Unconfirmed Complete and Partial Responses)
Complete Response(CR) is a complete disappearance of all disease with the exception of nodes. No new lesions. previously enlarged organs must have regressed and not be palpable. Bone marrow(BM) must be negative if positive at baseline. Normalization of markers. CR Unconfirmed (CRU) does not qualify for CR above, due to a residual nodal mass or an indeterminate BM. Partial Response(PR) is a 50% decrease in the sum of products of greatest diameters (SPD) for up to 6 identified dominant lesions, including spleenic and hepatic nodules from baseline. No new lesions and no increase in the size of liver, spleen or other nodes.
Measured: Assessed 200 days and 365 days after initiation of therapy and then every 6 months until death
Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
Adverse Events (AEs) are reported by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 2.0. For each patient, worst grade of each event type is reported. Grade 3 = Severe, Grade 4 = Life-threatening, Grade 5 = Fatal
Measured: Patients were assessed for adverse events at end of cycle 1-6 of CHOP or R-CHOP, the end of cycle 1-6 of CHOP and once 2 weeks after the completion of I-131 treatment. For either arm, once 3 months after removal from protocol treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jan 2003 (estimated)
- Study startMar 2001
- Primary completionSep 2011
- Study completionDec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for LymphomaStudies of the same condition, open and under way.
- More trials run by SWOG Cancer Research NetworkThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 571 participants (actual)
Sponsor and investigators
- Lead sponsor
- SWOG Cancer Research Network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI), Cancer and Leukemia Group B, Eastern Cooperative Oncology Group
- Responsible party
- Sponsor
- Investigators
- Oliver W. Press, MD, PhD, Study chair, Fred Hutchinson Cancer CenterMyron S. Czuczman, MD, Study chair, Roswell Park Cancer InstituteSandra J. Horning, MD, Study chair, Stanford University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00006721
- Sponsor's protocol ID
- CDR0000068321
- Other IDs
- U10CA032102, S0016, CALGB-50102, S0016
- Status last verified
- Feb 2026
- First submitted
- 6 Dec 2000
- Last updated
- 16 Mar 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: https://swog.org/Visitors/Download/Policies/Policy43.pdf
Publications
Shadman M, LeBlanc M, Rimsza L, Leonard JP, Smith SM, Li H, Friedberg JW. Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial. JAMA Oncol. 2026 Apr 1;12(4):394-401. doi: 10.1001/jamaoncol.2026.0042.
PubMed 41746629Filip D, Litzmanova K, Michaelou A, Kledus F, Devan J, Boudny M, Hoferkova E, Sharma S, Seda V, Zeni PF, Borsky M, Matulova K, Kren L, Oppelt J, Blavet N, Hejret V, Urik M, Mareckova A, Rimsza LM, Kamaradova K, Belada D, Sykorova A, Mocikova H, Trneny M, Prouzova Z, Evans AG, Danilov A, Horn H, Ott G, Staber P, Mayer J, Friedberg JW, Janikova A, Mraz M. Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma. Leukemia. 2026 Apr;40(4):759-772. doi: 10.1038/s41375-026-02868-8. Epub 2026 Feb 19.
PubMed 41714403Rutherford SC, Yin J, Pederson L, Perez Burbano G, LaPlant B, Shadman M, Li H, LeBlanc ML, Kenkre VP, Hong F, Blum KA, Dockter T, Martin P, Jung SH, Grant B, Rosenbaum C, Ujjani C, Barr PM, Unger JM, Cheson BD, Bartlett NL, Kahl B, Friedberg JW, Mandrekar SJ, Leonard JP. Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials. J Clin Oncol. 2023 Jan 10;41(2):336-342. doi: 10.1200/JCO.21.02301. Epub 2022 Jul 5.
PubMed 35787017Shadman M, Li H, Rimsza L, Leonard JP, Kaminski MS, Braziel RM, Spier CM, Gopal AK, Maloney DG, Cheson BD, Dakhil S, LeBlanc M, Smith SM, Fisher RI, Friedberg JW, Press OW. Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. J Clin Oncol. 2018 Mar 1;36(7):697-703. doi: 10.1200/JCO.2017.74.5083. Epub 2018 Jan 22.
PubMed 29356608Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol. 2013 Jan 20;31(3):314-20. doi: 10.1200/JCO.2012.42.4101. Epub 2012 Dec 10.
PubMed 23233710
Study at a glance
From the registry record, last updated by the sponsor on 16 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase III Trial of CHOP Plus Rituximab vs CHOP Plus Iodine-131-Labeled Monoclonal Anti-B1 Antibody (Tositumomab) for Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas
- ClinicalTrials.gov ID
- NCT00006721
- Acronym / sponsor ID
- CDR0000068321
- Conditions
- Lymphoma
- Keywords
- stage III grade 1 follicular lymphoma, stage III grade 2 follicular lymphoma, stage III grade 3 follicular lymphoma, stage IV grade 1 follicular lymphoma, stage IV grade 2 follicular lymphoma, stage IV grade 3 follicular lymphoma, contiguous stage II grade 1 follicular lymphoma, contiguous stage II grade 2 follicular lymphoma
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 571 participants (actual)
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Collaborators
- National Cancer Institute (NCI), Cancer and Leukemia Group B, Eastern Cooperative Oncology Group
- Study start
- Mar 2001
- Primary completion
- Sep 2011 (actual)
- Study completion
- Dec 2025 (actual)
- First posted
- 27 Jan 2003 (estimated)
- Results
- Posted 26 Feb 2013
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver radioactive tumor-killing substances to them without harming normal cells. It is not yet known which monoclonal antibody plus combination chemotherapy regimen is more effective in treating non-Hodgkin's lymphoma.
PURPOSE: This randomized phase III trial is comparing 2 different monoclonal antibodies given together with combination chemotherapy to see how well they work in treating patients with newly-diagnosed non-Hodgkin's lymphoma.
Detailed description
OBJECTIVES:
- Compare the progression-free survival and overall survival of patients with newly diagnosed follicular non-Hodgkin's lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with or without either rituximab or iodine I 131 tositumomab (monoclonal antibody anti-B1). (CHOP chemotherapy alone arm closed to accrual as of 12/15/02)
- Compare the response rate of these patients treated with these regimens.
- Compare the toxic effects of these regimens in these patients.
- Compare the molecular remission rates of this patient population treated with these regimens.
- Determine the incidence and time to development of human anti-mouse antibody positivity.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to whether microglobulin is greater than upper limit of normal (yes vs no). Patients are randomized to 1 of 3 treatment arms. (Arm I closed to accrual as of 12/15/02)
- Arm I (CHOP only): Patients receive cyclophosphamide IV over 15 minutes, doxorubicin IV over 5-20 minutes, and vincristine IV over 5-15 minutes on day 1. Patients also receive oral prednisone daily on days 1-5. Treatment continues every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. (Arm I closed to accrual as of 12/15/02)
- Arm II (CHOP + rituximab): Patients receive cyclophosphamide IV over 15 minutes, doxorubicin IV over 5-20 minutes, and vincristine IV over 5-15 minutes on days 8, 29, 50, 71, 92, and 113. Patients also receive oral prednisone daily on days 8-12, 29-33, 50-54, 71-75, and 113-117 and rituximab IV over 4-6 hours on days 1, 6, 48, 90, 134, and 141.
- Arm III (CHOP + tositumomab): Patients receive chemotherapy as in arm I and tositumomab (monoclonal antibody anti-B1) IV over 1 hour followed by iodine I 131 tositumomab IV over 20 minutes on days 134 and 141.
Patients are followed on day 200, at 1 year, every 6 months for 2 years, and then annually thereafter.
PROJECTED ACCRUAL: Approximately 500 patients (250 per treatment arm) will be accrued for this study within 5.5 years. (Arm I closed to accrual as of 12/15/02)
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Arm I (CHOP only) | Active comparator | Drug: cyclophosphamide, Drug: doxorubicin, Drug: prednisone, Drug: vincristinePatients receive cyclophosphamide IV over 15 minutes, doxorubicin IV over 5-20 minutes, and vincristine IV over 5-15 minutes on day 1. Patients also receive oral prednisone daily on days 1-5. Treatment continues every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. (Arm I closed to accrual as of 12/15/02) |
| Arm II (CHOP + rituximab) | Experimental | Biological: rituximab, Drug: cyclophosphamide, Drug: doxorubicin, Drug: prednisone, Drug: vincristinePatients receive cyclophosphamide IV over 15 minutes, doxorubicin IV over 5-20 minutes, and vincristine IV over 5-15 minutes on days 8, 29, 50, 71, 92, and 113. Patients also receive oral prednisone daily on days 8-12, 29-33, 50-54, 71-75, and 113-117 and rituximab IV over 4-6 hours on days 1, 6, 48, 90, 134, and 141. |
| Arm III (CHOP + tositumomab) | Experimental | Drug: cyclophosphamide, Drug: doxorubicin, Drug: prednisone, Drug: vincristine, Radiation: tositumomabPatients receive chemotherapy as in arm I and tositumomab (monoclonal antibody anti-B1) IV over 1 hour followed by iodine I 131 tositumomab IV over 20 minutes on days 134 and 141. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| rituximabAlso: rituxanGiven IV | Biological | Arm II (CHOP + rituximab) |
| cyclophosphamideAlso: cytoxanGiven IV | Drug | Arm I (CHOP only), Arm II (CHOP + rituximab), Arm III (CHOP + tositumomab) |
| doxorubicinAlso: adriamycinGiven IV | Drug | Arm I (CHOP only), Arm II (CHOP + rituximab), Arm III (CHOP + tositumomab) |
| prednisoneAlso: steroidGiven orally | Drug | Arm I (CHOP only), Arm II (CHOP + rituximab), Arm III (CHOP + tositumomab) |
| vincristineAlso: oncovinGiven IV | Drug | Arm I (CHOP only), Arm II (CHOP + rituximab), Arm III (CHOP + tositumomab) |
| tositumomabGiven IV | Radiation | Arm III (CHOP + tositumomab) |
Primary outcome
Progression-free Survival at 2 Years
Time frame: 0-2 years
Measured from time of registration to date of of first observation of progression/relapse, or death due to any cause, or last contact date
Progression-free Survival at 5 Years
Time frame: 0-5 years
Measured from time of registration to date of of first observation of progression/relapse, or death due to any cause, or last contact date
Overall Survival at 2 Years
Time frame: 0-2 years
Measured from date of registration to date of death due to any cause
Overall Survival at 5 Years
Time frame: 0-5 years
Measured from date of registration to date of death due to any cause
2 secondary outcomes
Objective Response (Confirmed and Unconfirmed Complete and Partial Responses)
Time frame: Assessed 200 days and 365 days after initiation of therapy and then every 6 months until death
Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
Time frame: Patients were assessed for adverse events at end of cycle 1-6 of CHOP or R-CHOP, the end of cycle 1-6 of CHOP and once 2 weeks after the completion of I-131 treatment. For either arm, once 3 months after removal from protocol treatment
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Mar 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 41746629Shadman M, LeBlanc M, Rimsza L, Leonard JP, Smith SM, Li H, Friedberg JW. Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial. JAMA Oncol. 2026 Apr 1;12(4):394-401. doi: 10.1001/jamaoncol.2026.0042.
- Derived from this study: PubMed 41714403Filip D, Litzmanova K, Michaelou A, Kledus F, Devan J, Boudny M, Hoferkova E, Sharma S, Seda V, Zeni PF, Borsky M, Matulova K, Kren L, Oppelt J, Blavet N, Hejret V, Urik M, Mareckova A, Rimsza LM, Kamaradova K, Belada D, Sykorova A, Mocikova H, Trneny M, Prouzova Z, Evans AG, Danilov A, Horn H, Ott G, Staber P, Mayer J, Friedberg JW, Janikova A, Mraz M. Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma. Leukemia. 2026 Apr;40(4):759-772. doi: 10.1038/s41375-026-02868-8. Epub 2026 Feb 19.
- Derived from this study: PubMed 35787017Rutherford SC, Yin J, Pederson L, Perez Burbano G, LaPlant B, Shadman M, Li H, LeBlanc ML, Kenkre VP, Hong F, Blum KA, Dockter T, Martin P, Jung SH, Grant B, Rosenbaum C, Ujjani C, Barr PM, Unger JM, Cheson BD, Bartlett NL, Kahl B, Friedberg JW, Mandrekar SJ, Leonard JP. Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials. J Clin Oncol. 2023 Jan 10;41(2):336-342. doi: 10.1200/JCO.21.02301. Epub 2022 Jul 5.
- Derived from this study: PubMed 29356608Shadman M, Li H, Rimsza L, Leonard JP, Kaminski MS, Braziel RM, Spier CM, Gopal AK, Maloney DG, Cheson BD, Dakhil S, LeBlanc M, Smith SM, Fisher RI, Friedberg JW, Press OW. Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. J Clin Oncol. 2018 Mar 1;36(7):697-703. doi: 10.1200/JCO.2017.74.5083. Epub 2018 Jan 22.
- Derived from this study: PubMed 23233710Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol. 2013 Jan 20;31(3):314-20. doi: 10.1200/JCO.2012.42.4101. Epub 2012 Dec 10.
- Individual participant dataSharing planned: Yes. https://swog.org/Visitors/Download/Policies/Policy43.pdf
Related trials for Lymphoma
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
RecruitingPhase 2
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
Non-hodgkin Lymphoma
RecruitingObservational study
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Cutaneous T-cell Lymphoma, Sezary Syndrome
Not yet recruitingPhase 1
Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma
Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma
Active, not recruitingPhase 2
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Oliver W. Press, MD, PhD study chair
Fred Hutchinson Cancer Center
Myron S. Czuczman, MD study chair
Roswell Park Cancer Institute
Sandra J. Horning, MD study chair
Stanford University
259 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing rituximab, cyclophosphamide and doxorubicin in people with Lymphoma, run by SWOG Cancer Research Network at 259 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 259 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 26 Feb 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Progression-free Survival at 2 Years (time frame: 0-2 years). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00006721, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Mar 2026.